


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-164)                              CRENIGACESTAT  
PRONUNCIATION                              kren" i gay' se stat  
THERAPEUTIC CLAIM                        Antineoplastic

CHEMICAL NAMES

1. Butanamide, *N*-[(1*S*)-2-[[*(7S)*-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5*H*-pyrido[3,2-*a*][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-
2. *N*-[(2*S*)-1-[[*(7S)*-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5*H*-pyrido[3,2-*a*][3]benzazepin-7-yl]amino}-1-oxopropan-2-yl]-4,4,4-trifluorobutanamide
3. 4,4,4-trifluoro-*N*- [(1*S*)-2-[[*(7S)*-5-(2-hydroxyethyl)-6-oxo-7*H*-pyrido[2,3-*d*][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide

STRUCTURAL FORMULA



MOLECULAR FORMULA                        C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>  
MOLECULAR WEIGHT                            464.4  
TRADEMARK                                    None as yet  
SPONSOR                                        Eli Lilly and Company  
CODE DESIGNATIONS                           LY3039478  
CAS REGISTRY NUMBER                       1421438-81-4  
UNII    923X28214S  
WHO NUMBER                                   10655

SCS